Home >  Haixin > Development History

Development History

history of HAIXIN Development History

  • 2017
    In May 2017, the Board of Directors of the Company adopted the Five-year Development Plan (2017-2021) of Shanghai Haixin Group Co., Ltd. after deliberation, and decided that the Company was to form a brand new industry pattern of "coordinated development of one main body and two wings" with the medical and health industry as the main body and the real estate property and financial investment as the auxiliary industries.
  • 2016
    On December 28, 2016, the Company signed a Strategic Cooperation Agreement with the People's Government of Dongjing Town, Songjiang District, Shanghai, and Shanghai Lingang Holding Co., Ltd. The three parties were interested in complementary advantages and focused on the development, construction, management and supporting services of industrial parks, forming close strategic partnership.
  • 2015
    As of 2015, Haixin biological, a holding subsidiary of the Company has contacted more than 10 hospitals, initially established a cooperation intention, and basically established the Phase III clinical research program of APDC project.
  • 2014
    April 11, 2014, Haixin Pharmaceutical, a holding subsidiary of the Company, was listed on the National SME Share Transfer System. Its securities were referred to as "Haixin Pharmaceutical" and the securities code was "430699".
  • 2013
    In 2013, the Board of Directors of the Company agreed to borrow 20 million CNY from Haixin Biology, one of its subsidiaries for initiating Phase III clinical trials of APDC project. Twenty hospitals located in Shanghai, Zhejiang, Beijing and other places were initially selected as clinical research units for Phase Ⅲ clinical research program of APDC project. The "data management system of cell therapy products" was established, and the data management system was updated and optimized.
  • 2012
    On July 26, 2012, Haixin Biology, a holding subsidiary of the Company, obtained the Drug Clinical Trial Approval issued by the State Drug Administration, which agreed the phase III clinical trial for antigen-sensitized human dendritic cells (APDC).
  • 2007
    On December 27, 2007, Changjiang Securities was successfully backdoor-listed, and the Changjiang Securities shares held by the Company got a substantial appreciation.
  • 2005
    In November 2005, Shanghai Haixin Toys, a holding subsidiary of the Company became one of the producers and dealers of Beijing 2008 Olympic Games' mascot "Fuwa". The sales of Fuwa were booming.
  • 2003
    In 2003, the Company, Changjiang Securities and Wuhan Iron and Steel jointly established Changxin Asset Management Company. The registered capital was 90 million CNY, and the Company’s contribution accounted for 34.33%.
  • 2002
    In May 2002, the Company invested USD 16.372 million and successfully acquired the textile division of American GLENOIT with a history of 70 years to get trademarks of 46 brands that could be used permanently.
  • 2001

    Since 2001, the Company has successively held shares and participated in shares of eight pharmaceutical companies, including Xi'an Haixin, Gannan Haixin, Suzhong Haixin, Suzhong Pharmaceutical, Haixin Pharmaceutical Sales Company and Haixin biotechnology Company, preliminarily forming an industrial chain of pharmaceutical research, development, production and sales.

    In 2001, the Company invested CNY 231 million in Changjiang Securities Company, accounting for ten percent of its registered capital.

  • 2000
    In 2000, the Company made public offering of A-shares of 60 million shares to the public. After deducting the related expenses, the Company raised a total of CNY 812 million, gradually entering the reform stage of diversified development.
  • 1999

    In 2000, the main business of the Company basically formed an industry chain of spinning, fabrics, blankets, toys and clothing textile with plush fabric as the core.



  • 1995
    On December 28, 1995, "Shanghai Haixin Co., Ltd." was renamed as "Shanghai Haixin Group Co., Ltd." (hereinafter referred to as "Company") after being approved by the State Administration for Industry and Commerce of the People's Republic of China.
  • 1993


    On July 1, 1993, Wu Bangguo, member of the Political Bureau of the CPC Central Committee and secretary of the Shanghai Municipal Committee of the CPC then, inspected Haixin Co., Ltd. (Songjiang).

    On November 1, 1993, Haixin Co., Ltd. issued CNY stock of 10 million shares to the public (abbreviation of securities: Haixin stock, stock code: 600851) and the paid-in capital was CNY 68.95 million.  On April 4, 1994, it was listed in Shanghai Stock Exchange.
    On November 23, 1993, Haixin Co., Ltd. issued CNY special stock of 35 million shares to overseas legal persons and natural persons (abbreviation of securities: Haixin B shares, stock code: 900917) , and the paid-in capital was USD23.03 million. On December 8 of the same year, it was listed in the Shanghai Stock Exchange.


  • 1986
     ●In September 1986, Shanghai Haixin Limited, a Sino-foreign joint venture was established with a registered capital of USD 3 million after being approved by the Foreign Economic and Trade Commission of Shanghai Municipal People's Government. After the two capital increases of USD 7 million in 1990 and 1992, the Company’s registered capital was more than USD 10 million.
1986-2017 Haixin Group Shanghai Co., Ltd. All rights reserved 沪ICP备 05000511号 Integrity website certification
微信